Pulmonary rehabilitation and clinical trial design in patients with severe COPD

Steven C. Springmeyer, Richard Casaburi, Barry Make, Paul Jones, Robert A Wise

Research output: Contribution to journalArticle

Abstract

Pulmonary rehabilitation confers significant benefit to patients with COPD. The beneficial effects are seen in dyspnea and health-related quality of life. These measures are often considered in clinical trials as study endpoints. Pulmonary rehabilitation may affect the study population and study enrollment in clinical trials of other therapies in COPD, so it is important to anticipate the effects of pulmonary rehabilitation when designing and performing clinical trials. We review pulmonary rehabilitation and clinical trial design in patients with severe COPD. No publications were found that specifically address the impact of pulmonary rehabilitation on study design. No consensus statements, guidelines, or pharmaceutical studies in COPD were found that addressed pulmonary rehabilitation and study design. Pre-operative pulmonary rehabilitation is almost universal with lung transplantation and lung volume reduction surgery (LVRS). The National Emphysema Treatment Trial (NETT) included a mandatory pre-operative pulmonary rehabilitation program. The NETT reported that the mandatory pre-operative program reduced their study population by 32%. The NETT pre-operative program is required for Medicare reimbursement for LVRS, restricting the surgery to the subgroup of patients completing the program. Pulmonary rehabilitation can affect selection of the study population, study enrollment, outcome measures, and influence whether the results can be generalized to other patients. Clinical trials with medications, devices, or surgery for severe COPD should consider study designs that anticipate the significant effects of pulmonary rehabilitation.

Original languageEnglish (US)
Pages (from-to)305-309
Number of pages5
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume5
Issue number5
DOIs
StatePublished - Oct 2008

Fingerprint

Chronic Obstructive Pulmonary Disease
Rehabilitation
Clinical Trials
Lung
Emphysema
Pneumonectomy
Population
Lung Transplantation
Therapeutics
Medicare
Dyspnea
Publications
Quality of Life
Outcome Assessment (Health Care)
Guidelines
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Pulmonary disease (chronic obstructive)
  • Rehabilitation
  • Therapeutic human experimentation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pulmonary rehabilitation and clinical trial design in patients with severe COPD. / Springmeyer, Steven C.; Casaburi, Richard; Make, Barry; Jones, Paul; Wise, Robert A.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 5, No. 5, 10.2008, p. 305-309.

Research output: Contribution to journalArticle

Springmeyer, Steven C. ; Casaburi, Richard ; Make, Barry ; Jones, Paul ; Wise, Robert A. / Pulmonary rehabilitation and clinical trial design in patients with severe COPD. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2008 ; Vol. 5, No. 5. pp. 305-309.
@article{42c4a476edec4665b4c74158f9691215,
title = "Pulmonary rehabilitation and clinical trial design in patients with severe COPD",
abstract = "Pulmonary rehabilitation confers significant benefit to patients with COPD. The beneficial effects are seen in dyspnea and health-related quality of life. These measures are often considered in clinical trials as study endpoints. Pulmonary rehabilitation may affect the study population and study enrollment in clinical trials of other therapies in COPD, so it is important to anticipate the effects of pulmonary rehabilitation when designing and performing clinical trials. We review pulmonary rehabilitation and clinical trial design in patients with severe COPD. No publications were found that specifically address the impact of pulmonary rehabilitation on study design. No consensus statements, guidelines, or pharmaceutical studies in COPD were found that addressed pulmonary rehabilitation and study design. Pre-operative pulmonary rehabilitation is almost universal with lung transplantation and lung volume reduction surgery (LVRS). The National Emphysema Treatment Trial (NETT) included a mandatory pre-operative pulmonary rehabilitation program. The NETT reported that the mandatory pre-operative program reduced their study population by 32{\%}. The NETT pre-operative program is required for Medicare reimbursement for LVRS, restricting the surgery to the subgroup of patients completing the program. Pulmonary rehabilitation can affect selection of the study population, study enrollment, outcome measures, and influence whether the results can be generalized to other patients. Clinical trials with medications, devices, or surgery for severe COPD should consider study designs that anticipate the significant effects of pulmonary rehabilitation.",
keywords = "Pulmonary disease (chronic obstructive), Rehabilitation, Therapeutic human experimentation",
author = "Springmeyer, {Steven C.} and Richard Casaburi and Barry Make and Paul Jones and Wise, {Robert A}",
year = "2008",
month = "10",
doi = "10.1080/15412550802363469",
language = "English (US)",
volume = "5",
pages = "305--309",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Pulmonary rehabilitation and clinical trial design in patients with severe COPD

AU - Springmeyer, Steven C.

AU - Casaburi, Richard

AU - Make, Barry

AU - Jones, Paul

AU - Wise, Robert A

PY - 2008/10

Y1 - 2008/10

N2 - Pulmonary rehabilitation confers significant benefit to patients with COPD. The beneficial effects are seen in dyspnea and health-related quality of life. These measures are often considered in clinical trials as study endpoints. Pulmonary rehabilitation may affect the study population and study enrollment in clinical trials of other therapies in COPD, so it is important to anticipate the effects of pulmonary rehabilitation when designing and performing clinical trials. We review pulmonary rehabilitation and clinical trial design in patients with severe COPD. No publications were found that specifically address the impact of pulmonary rehabilitation on study design. No consensus statements, guidelines, or pharmaceutical studies in COPD were found that addressed pulmonary rehabilitation and study design. Pre-operative pulmonary rehabilitation is almost universal with lung transplantation and lung volume reduction surgery (LVRS). The National Emphysema Treatment Trial (NETT) included a mandatory pre-operative pulmonary rehabilitation program. The NETT reported that the mandatory pre-operative program reduced their study population by 32%. The NETT pre-operative program is required for Medicare reimbursement for LVRS, restricting the surgery to the subgroup of patients completing the program. Pulmonary rehabilitation can affect selection of the study population, study enrollment, outcome measures, and influence whether the results can be generalized to other patients. Clinical trials with medications, devices, or surgery for severe COPD should consider study designs that anticipate the significant effects of pulmonary rehabilitation.

AB - Pulmonary rehabilitation confers significant benefit to patients with COPD. The beneficial effects are seen in dyspnea and health-related quality of life. These measures are often considered in clinical trials as study endpoints. Pulmonary rehabilitation may affect the study population and study enrollment in clinical trials of other therapies in COPD, so it is important to anticipate the effects of pulmonary rehabilitation when designing and performing clinical trials. We review pulmonary rehabilitation and clinical trial design in patients with severe COPD. No publications were found that specifically address the impact of pulmonary rehabilitation on study design. No consensus statements, guidelines, or pharmaceutical studies in COPD were found that addressed pulmonary rehabilitation and study design. Pre-operative pulmonary rehabilitation is almost universal with lung transplantation and lung volume reduction surgery (LVRS). The National Emphysema Treatment Trial (NETT) included a mandatory pre-operative pulmonary rehabilitation program. The NETT reported that the mandatory pre-operative program reduced their study population by 32%. The NETT pre-operative program is required for Medicare reimbursement for LVRS, restricting the surgery to the subgroup of patients completing the program. Pulmonary rehabilitation can affect selection of the study population, study enrollment, outcome measures, and influence whether the results can be generalized to other patients. Clinical trials with medications, devices, or surgery for severe COPD should consider study designs that anticipate the significant effects of pulmonary rehabilitation.

KW - Pulmonary disease (chronic obstructive)

KW - Rehabilitation

KW - Therapeutic human experimentation

UR - http://www.scopus.com/inward/record.url?scp=55249091407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249091407&partnerID=8YFLogxK

U2 - 10.1080/15412550802363469

DO - 10.1080/15412550802363469

M3 - Article

C2 - 18972279

AN - SCOPUS:55249091407

VL - 5

SP - 305

EP - 309

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 5

ER -